Debbie Rigby takes a look at the latest in research news
Elevated total and LDL cholesterol predispose patients to an increased risk of cardiovascular disease and mortality. An extensive amount of research supports the use of statins for secondary prevention. Myalgia remains the most commonly reported adverse effect with statins. New-onset diabetes has also been observed in clinical trials, but more commonly in patients with increased diabetes risk. The negative effects of statins on memory and cognition have been noted anecdotally in many case reports but have not been substantiated in larger trials.
US Pharm. 2019;44(2):16-24.
The benefit of aspirin use for secondary prevention of cardiovascular disease is well established; the efficacy of aspirin use for primary prevention, however, is less evident. High-risk populations, such as patients with diabetes and those with a 10-year cardiovascular risk exceeding 10%, may benefit from low-dose aspirin primary prevention.
US Pharm. 2016;41(2):22-25.
This review aimed to investigate and explore pharmacist-driven chronic pain educational and medication management interventions in community pharmacies on an international level, and thereby identify if there are potential benefits in modelling and incorporating these interventions in the Australian community. Results demonstrated that there were improvements in the pain scores, depression/anxiety scales and physical functionality in patient groups receiving the pharmacist driven-interventions, thereby highlighting the clinical benefit of these interventions in chronic pain.
Pharmacy Practice 2019;17(1):1410.
A study conducted at the Maryborough hospital, Queensland with 198 patients showed hospitalised patients are unaware of medication management services ((MedsCheck, Diabetes MedsCheck and Home Medication Review) that could reduce frequency of re-hospitalisation. The authors concluded that community and hospital pharmacists can play a major role increasing patients’ awareness of the availability of these services.
International Journal of Clinical Pharmacy 2019;41(1):189-97.